3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The administration of allogeneic third party derived LMP specific-CTLs (special peripheral
blood cells from another person) that are made specific to fight EBV infection) in Children,
Adolescents and Young Adults (CAYA) with EBV-associated refractory or relapsed lymphoma will
be feasible ( able to be done), safe and well tolerated (no unexpected serious events will
occur). In addition, potential donors who are EBV positive will be enrolled to donate
peripheral blood to help build a bank of these specific EBV fighting cell lines.
Phase:
Phase 1
Details
Lead Sponsor:
New York Medical College
Collaborators:
Baylor College of Medicine Children's National Research Institute Children's Research Institute City of Hope Medical Center Johns Hopkins University M.D. Anderson Cancer Center Ohio University University of Michigan University of Utah